Next-generation anti-IgE monoclonal antibody becomes the first biologic candidate in China to file a BLA for seasonal ...
Preliminary MAGMAP trial results in 62 patients show a 96% sentinel node identification rate and no false negatives in the ...
Blood-brain barrier-penetrating therapy targets MPS IIIB, an ultra-rare lysosomal storage disorder with no currently approved ...
The FACSDiscover A7 Cell Analyzer sets a new standard for experimental standardization in flow cytometry Waters Corporation ...
Icosagen, a private European protein therapeutics CRDMO, and EPOK Therapeutics Inc., a pre-clinical-stage biopharmaceutical ...
New stackable chambers provide precise environmental control, remote monitoring and data logging for pharmaceutical, biotech, ...
Combination brings single-cell and spatial transcriptomics together with GLP/GCLP-compliant qPCR and bioanalytical ...
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet ...
Accro Bioscience announced tha t AC-101 tablets have been included in the Rare Diseases Innovative Drug Development ...
Twenty-six figures, each cited to a primary disclosure with its date attached, that together tell the Asia-Pacific biopharma year: where the capital concentrated, what the deals validated, how a ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) ...
China-developed HER2-targeted ADC delivers 11.1-month median PFS versus 4.4 months with T-DM1 in patients with HER2-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results